Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer
ConclusionFrom the perspective of the Chinese healthcare system, this study ’s findings suggested that first-line TC represents a cost-effective strategy for patients with advanced NSCLC. However, the cost-effectiveness of first-line TC varied across different subgroups when considering predictive biomarkers.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Study